Breaking News Instant updates and real-time market news.

AVXS

AveXis

$44.55

2.36 (5.59%)

07:42
10/06/16
10/06
07:42
10/06/16
07:42

AveXis attractive acquisition target, price target to $71 at Goldman

Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.

  • 06

    Nov

AVXS AveXis
$44.55

2.36 (5.59%)

08/17/16
WELS
08/17/16
UPGRADE
WELS
Outperform
AveXis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded AveXis (AVXS) to Outperform after speaking to five experts in spinal muscular atrophy. The experts were impressed with both Ionis Pharmaceuticals (IONS)/Biogen's (BIIB) nusinersen and AveXis' gene therapy AVXS101, and suggested that likely incomplete restoration of normal neuromuscular phenotype could prompt combination use of both treatments, Birchenough tells investors in a research note. The analyst raised his price target range for AveXis shares to $56-$61 from $30-$32. The stock closed yesterday down $1.91 to $41.66.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies thinks it found baby in AveXis trial that is walking
Jefferies analyst Biren Amin believes a video posted online of a baby walking has a "strong likelihood" of being a patient in AveXis' AVXS-101 trial. AVXS-101 is a gene therapy candidate in Phase I testing for spinal muscular atrophy. The near 20 month old's achievement to walk "is significant" given that she is a Type 1 SMA baby with 2 copy number and would not in any normal circumstance be expected to walk, Amin tells investors in a research note. The analyst points out that his finding online comes ahead of AveXis' plan to disclose patient data on motor milestones from its Phase 1 trial later this year. To reflect increased confidence in AVXS-101's prospects, Amin raised his price target for the shares to $50 from $42. The clinical-stage gene therapy company, formerly known as Biolife Cell Bank, closed Friday up 83c to $41.72.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.

TODAY'S FREE FLY STORIES

INN

Summit Hotel Properties

$15.46

0.1 (0.65%)

05:20
09/26/17
09/26
05:20
09/26/17
05:20
Upgrade
Summit Hotel Properties rating change  »

Summit Hotel Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DRE

Duke Realty

$29.28

0.17 (0.58%)

05:17
09/26/17
09/26
05:17
09/26/17
05:17
Downgrade
Duke Realty rating change  »

Duke Realty downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$29.56

0.05 (0.17%)

05:15
09/26/17
09/26
05:15
09/26/17
05:15
Downgrade
Rexford Industrial rating change  »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCO

Taubman Centers

$50.00

0.86 (1.75%)

05:14
09/26/17
09/26
05:14
09/26/17
05:14
Downgrade
Taubman Centers rating change  »

Taubman Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 11

    Oct

KIM

Kimco Realty

$19.58

0.4 (2.09%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
Kimco Realty rating change  »

Kimco Realty upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GGP

GGP

$20.75

0.25 (1.22%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
GGP rating change  »

GGP upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAC

Macerich

$54.16

1.44 (2.73%)

05:10
09/26/17
09/26
05:10
09/26/17
05:10
Upgrade
Macerich rating change  »

Macerich upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$81.23

-1.46 (-1.77%)

05:06
09/26/17
09/26
05:06
09/26/17
05:06
Initiation
Dycom initiated  »

Dycom initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PNC

PNC Financial

$133.52

0.09 (0.07%)

, GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

05:04
09/26/17
09/26
05:04
09/26/17
05:04
Downgrade
PNC Financial, Goldman Sachs, Wells Fargo, Morgan Stanley, JPMorgan rating change  »

PNC Financial downgraded…

PNC

PNC Financial

$133.52

0.09 (0.07%)

GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

WFC

Wells Fargo

$54.03

-0.22 (-0.41%)

MS

Morgan Stanley

$47.74

-0.48 (-1.00%)

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 12

    Oct

  • 13

    Oct

  • 13

    Oct

  • 17

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

05:01
09/26/17
09/26
05:01
09/26/17
05:01
Downgrade
JPMorgan rating change  »

JPMorgan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 12

    Oct

  • 22

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JWN

Nordstrom

$47.32

0.44 (0.94%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BMY

Bristol-Myers

$63.19

-0.17 (-0.27%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bristol-Myers management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

MCO

Moody's

$138.78

0.75 (0.54%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Moody's management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

ALB

Albemarle

$128.89

-5.4 (-4.02%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Albemarle management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

AFSI

AmTrust

$12.98

-0.3 (-2.26%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
AmTrust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

NEE

NextEra Energy

$146.82

0.46 (0.31%)

, AES

AES Corp.

$11.21

0.1 (0.90%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Wolfe Research to hold a conference »

Utilities & Power…

NEE

NextEra Energy

$146.82

0.46 (0.31%)

AES

AES Corp.

$11.21

0.1 (0.90%)

PEGI

Pattern Energy

$25.53

-0.37 (-1.43%)

LNT

Alliant Energy

$42.25

0.52 (1.25%)

AGR

Avangrid

$47.10

0.6 (1.29%)

PNW

Pinnacle West

$86.85

0.7 (0.81%)

ETR

Entergy

$77.76

1.01 (1.32%)

PEG

PSEG

$46.50

0.31 (0.67%)

AWK

American Water

$82.48

0.45 (0.55%)

CMS

CMS Energy

$47.10

0.63 (1.36%)

AEP

American Electric

$71.04

0.47 (0.67%)

D

Dominion

$78.02

0.98 (1.27%)

ED

Consolidated Edison

$82.24

0.65 (0.80%)

ES

Eversource

$61.47

0.76 (1.25%)

EIX

Edison International

$79.27

0.99 (1.26%)

DUK

Duke Energy

$85.14

0.89 (1.06%)

DTE

DTE Energy

$109.74

1.36 (1.25%)

FE

FirstEnergy

$31.11

0.22 (0.71%)

WEC

WEC Energy

$64.24

0.63 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 02

    Oct

  • 02

    Oct

  • 05

    Nov

  • 29

    Nov

DNOW

NOW Inc.

$13.26

0.27 (2.08%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

ALGT

Allegiant Travel

$133.95

3.85 (2.96%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Allegiant Travel management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XPER

Xperi

$24.70

-0.35 (-1.40%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Xperi management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

OZRK

Bank of the Ozarks

$45.90

0.34 (0.75%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bank of the Ozarks management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Consumer Confidence to be reported at 10:00 »

September Consumer…

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Citigroup to hold a forum »

Pan Asia Corporate Forum…

BGG

Briggs & Stratton

$22.93

0.24 (1.06%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Briggs & Stratton management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PLUS

ePlus

$87.95

-0.65 (-0.73%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
ePlus management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Breaking General news story  »

Federal Reserve Chair…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.